Citations

Clear

499 citation(s) found for "Tracy, PB".

Congenital myopathies in the adult neuromuscular clinic
Nicolau, Stefan , Liewluck, Teerin , Tracy, Jennifer A., Laughlin, Ruple S. , Milone, Margherita , Liewluck, T , Nicolau, Stefan

Mayo Clinic

Neurology Genetics | June 5, 2019 | Volume: 5 | Issue: 4 | Pages: No page available

10.1212/nxg.0000000000000341 | PMID 31321302 Get It

Functional control of electrophysiological network architecture using direct neurostimulation in humans
Khambhati, Ankit N. , Costantini, Julia , Ezzyat, Youssef , Solomon, Ethan A. , Jobst, Barbara C. , Sheth, Sameer A. , Seger, Sarah , Weiss, Shennan A. , Sperling, Michael R. , Gorniak, Richard , Rizzuto, Daniel S. , Kahana, Michael J. , Lucas, Timothy H., Bassett, Danielle S. , Sperling, Michael R , Weiss, Shennan A , Kahn, Ari E. , Gross, Robert E. , Zaghloul, Kareem A. , Worrell, Gregory A. , Lega, Bradley Charles , Das, Sandhitsu R. , Stein, Joel M. , Davis, Kathryn A. , Tracy, Joseph I. , Jobst, Barbara

Mayo Clinic

Network Neuroscience | May 28, 2019 | Volume: 3 | Issue: 3 | Pages: 848-877

10.1162/netn_a_00089 | PMID 31410383 Get It

Chronically implantable neurostimulation devices are becoming a clinically viable option for treating patients with neurological disease and psychiatric disorders. Neurostimulation offers the ability to probe and manipulate distributed networks of interacting brain areas in dysfunctional circuits. Here, we use tools from network control theory to examine the dynamic reconfiguration of functionally interacting neuronal ensembles during targeted neurostimulation of cortical and subcortical brain structures. By integrating multimodal intracranial recordings and diffusion-weighted imaging from patients with drug-resistant epilepsy, we test hypothesized structural and functional rules that predict altered patterns of synchronized local field potentials. We demonstrate the ability to predictably reconfigure functional interactions depending on stimulation strength and location. Stimulation of areas with structurally weak connections largely modulates the functional hubness of downstream areas and concurrently propels the brain towards more difficult-to-reach dynamical states. By using focal perturbations to bridge large-scale structure, function, and markers of behavior, our findings suggest that stimulation may be tuned to influence different scales of network interactions driving cognition.
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.
Makower, Della , Lively, Tracy , Saphner, Thomas J. , Keane, Maccon, Gomez, Henry Leonidas, Reddy, Pavan S. , Goggins, Timothy F., Toppmeyer, Deborah , Brufsky, Adam , Hayes, Daniel F. , Dees, Elizabeth Claire , Albain, Kathy S. , Gómez, Henry , Brufsky, Adam M , Sparano, Joseph A. , Gray, Robert J. , Mayer, Ingrid A. , Goetz, Matthew P. , Pritchard, Kathleen I. , Geyer, Charles E. , Olson, John A. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 503-503

10.1200/jco.2019.37.15_suppl.503 Get It

503 Background: TAILORx established that endocrine therapy (ET) alone is non-inferior to adjuvant chemotherapy (CT) plus ET in EBC and a 21-gene RS of 11-25, with some benefit if ≤50 years (y) with RS 16-25 (PMID: 29860917). We evaluated whether clinical risk (tumor size & histologic grade) provides additional prognostic information to RS, a secondary trial objective. Methods: Clinical risk by was assessed by Adjuvant! (version 8.0) using MINDACT criteria (PMID 27557300), defined as low clinical risk (LCR - tumor ≤3 cm and low grade, <2 cm and intermediate grade, or ≤1 cm and high grade) or high clinical risk (HCR -not meeting LCR criteria). Results: Of 9427 women with RS and clinical risk information, 70% were LCR and 30% HCR, with comparable distribution by age ( ≤50 vs. >50). The RS was 26-100 in 9% of LCR and 27% of HCR patients, with similar distributions by age. Although LCR/HCR provided additional prognostic information in each RS category for iDFS, including RS 0-10 (9-year rates 86.7% vs. 75.7% LCR vs. HCR), 11-25 (85.4% vs. 78.9%), and 26-100 (82.0% vs. 70.4%), iDFS rates were similar irrespective of CT (no vs. yes) in the entire RS 11-25 cohort whether LCR (85.8% vs. 85.1%) or HCR (79.8% vs. 77.9%). DRFI rates were also similar irrespective of CT in the RS 11-25 cohort or > 50y group whether LCR (96.0% vs. 96.1% overall; 96.5% vs. 96.0% > 50y) or HCR (92.3% vs. 89.9% overall; 91.7% vs. 90.7% >50y). For women ≤50y, the absolute reduction in distant recurrence from CT with a RS of 16-20 (N=923) was -0.2% (standard error [SE]±2.1%) for LCR vs. 6.5%(SE±4.9%) for HCR (vs. 1.6%[SE±1.9%] overall), whereas for a RS 21-25 (N=492) it was 6.4% (SE±4.9%) for LCR vs. 8.6% (SE±6.2%) for HCR (vs. 6.5%[SE±3.7%] overall). Conclusions: Clinical risk stratification provides additional prognostic information to the 21-gene RS, but not prediction of CT benefit in the overall TAILORx population or those > 50y, and facilitates more refined estimates of absolute CT benefit for women ≤50y with a RS 16-25. (Funded by National Cancer Institute, Komen Foundation, Breast Cancer Research Foundation). Clinical trial information: NCT00310180.
Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial
Albain, Kathy S. , Gray, RJ, Sparano, JA, Makower, D., Hayes, DF, Geyer, CE, Dees, EC, Goetz, MP, Olson, JA, Lively, Tracy , Badve, S, Saphner, TJ, Wagner, LI, Whelan, Timothy J. , Ellis, MJ, Wood, WC, Ravdin, P., Keane, MM, Gómez, HL, Reddy, P, Goggins, TF, Mayer, IA , Brufsky, Adam , Toppmeyer, D., Kaklamani, VG, Berenberg, JL, Abrams, Jeffrey S. , Sledge, GW, Gómez, Henry , Brufsky, Adam M , Pritchard, Kathleen I. , Saphner, Thomas J. , Paik, Soonmyung , Whelan, Timothy J

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 79 | Issue: 4_Supplement | Pages: GS4-07-GS4-07

10.1158/1538-7445.sabcs18-gs4-07 Get It

Abstract Background: Black race is associated with worse outcomes in localized hormone receptor (HR)-positive breast cancer in population-based and in clinical trial cohorts, whether using self-identified race (Albain et al. JNCI 2009 [PMID: 19584328; Sparano et al. JNCI 2012 [PMID: 22250182) or genetically-identified race (Schneider et al. J Precision Oncol 2017 [PMID: 29333527]). This disparity persists after adjustment for treatment delivery parameters (Hershman et al. JCO 2009 [PMID:19307504]). We evaluated clinicopathologic characteristics, treatment delivered and clinical outcomes in the Trial Assigning Individualized Options for Treatment (TAILORx) by race and ethnicity (Sparano et al. NEJM 2018 [PMID: 29860917]). Methods: The analysis included 9719 evaluable TAILORx participants. The association between clinical outcomes and race (white, black, Asian, other/unknown) and ethnicity (Hispanic vs. non-Hispanic) was examined, including invasive disease-free survival (iDFS), distant relapse-free interval (DRFI), relapse-free interval (RFI), and overall survival (OS). Proportional hazards models were fit including age (5 categories), tumor size (&gt;2 cm vs. &lt;=2 cm), histologic grade (high vs. medium vs. low vs. unknown), continuous recurrence score (RS), race, and ethnicity in the overall population and randomized treatment arms in the RS 11-25 cohort. Results: The study population included 8189 (84%) whites, 693 (7%) blacks, 405 (4%) Asians, and 432 (4%) with other/unknown race. Regarding ethnicity, 7635 (79%) were non-Hispanic, 889 (9%) Hispanic, and 1195 (12%) unknown. There was no significant difference in RS distribution (p=0.22) in blacks compared with whites, or in median (17 vs. 17) or mean RS (19.1 vs. 18.2). There was likewise no difference in Hispanic vs. non-Hispanic ethnicity for RS distribution (p=0.72) or median (17 vs. 17) or mean RS (18.5 vs. 18.0). Black race (39% vs. 30%) and Hispanic ethnicity (39% vs. 30%) were both associated with younger age (&lt;/=50 years) at diagnosis. The use and type of adjuvant chemotherapy and endocrine therapy, and duration of endocrine therapy, were similar in black (vs. white) and Hispanic (vs. non-Hispanic) populations. In proportional hazards models, black race (compared with white race) was associated with worse clinical outcomes in the entire population and in those with a RS 11-25 (see table). Hispanic ethnicity was generally associated with better outcomes (compared with non-Hispanic ethnicity). For the cohort with a RS of 11-25, there was no evidence for chemotherapy benefit for any racial or ethnic group. Race (black vs.white) and clinical outcomes in proportional hazards modelsClinical endpointEntire Population (N=693 black) Hazard ratio for eventRS 11-25 (N=471 black) Hazard ratio for eveniDFS1.33 (p=0.005)1.49 (p=0.001)DRFI1.21 (p=0.28)1.60 (p=0.02)RFI1.39 (p=0.02)1.80 (p&lt;0.001)OS1.52 (p=0.005)1.67 (p=0.003 Conclusions: In patients eligible and selected for participation in TAILORx, black women had worse clinical outcomes despite similar 21-gene assay RS results and comparable systemic therapy. This adds to an emerging body of evidence suggesting a biologic basis or other factors contributing to racial disparities in HR-positive breast cancer that requires further evaluation. Citation Format: Albain K, Gray RJ, Sparano JA, Makower DF, Pritchard KI, Hayes DF, Geyer, Jr. CE, Dees EC, Goetz MP, Olson, Jr. JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge, Jr. GW. Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS4-07.
The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas
Tracy, Sean , Novak, Anne J. , Allmer, Cristine, Farooq, Umar , Syrbu, Sergei , Link, Brian K. , Tracy, Sean I , Cerhan, James R , Link, Brian K , Farooq, Umar , Syrbu, Sergei , Larson, Melissa C. , Feldman, Andrew L. , Maurer, Matthew J. , Slager, Susan L. , Villasboas, José C. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | March 28, 2019 | Volume: 94 | Issue: 6 | Pages: 658-666

10.1002/ajh.25473 | PMID 30916801 Get It

AbstractIndolent B‐cell lymphomas other than follicular lymphoma account for up to 10% of all B‐cell neoplasms. While they typically follow a slowly progressive course, some patients experience rapid progression and early mortality. Prognostic scoring systems have not been adopted, hindering the ability of clinicians or researchers to predict outcomes, or risk‐stratify patients during clinical trials. To address this, we evaluated the utility of existing prognostic indices and novel, early disease‐related outcomes, to predict subsequent long term survival. Baseline characteristics and outcomes data were generated from a longitudinal cohort study that prospectively enrolled 632 patients newly diagnosed with marginal zone lymphoma, lymphoplasmacytic lymphomas, or B‐cell lymphomas not otherwise specified, beginning in 2002. The International Prognostic Index (IPI), Follicular Lymphoma International Prognostic Index (FLIPI), and MALT International prognostic index (MALT‐IPI) demonstrated c‐statistics that ranged from 0.593‐0.612 for event‐free survival (EFS), and 0.683‐0.714 for overall survival (OS). Patients who attained event‐free survival at 12 months (EFS12) experienced similar mortality to the US general population (standardized mortality ratio [SMR] 1.19; 95% CI 0.95‐1.46). Patients who did not attain EFS12 had subsequent worse morality (SMR 3.14 (95% CI 2.05‐4.59). The MALT‐IPI demonstrated utility in predicting subsequent long‐term outcomes among patients with non‐follicular indolent B‐cell lymphomas. This index should be used by clinicians giving guidance to patients at the time of initial diagnosis, and risk stratification during clinical studies. The divergent long‐term outcomes experienced by patients who do or do not attain EFS12 suggest there exists a subset of patients who harbor high‐risk disease. Future research efforts should focus on methods to identify these patients at the time of diagnosis, in order to enable risk‐tailored therapy.
Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry
Bradley, Corey , Wang, Tracy Y., Li, Shuang , Robinson, Jennifer G. , Roger, Véronique L. , Goldberg, Anne C. , Louie, Michael J. , Lee, L. Veronica, Virani, Salim S. , Peterson, Eric D. , Návar, Ann Marie

Mayo Clinic

Journal of the American Heart Association | March 27, 2019 | Volume: 8 | Issue: 7 | Pages: No page available

10.1161/jaha.118.011765 | PMID 30913959 Get It

Background Many adults eligible for statin therapy for cardiovascular disease prevention are untreated. Our objective was to investigate patient‐reported reasons for statin underutilization, including noninitiation, refusal, and discontinuation. Methods and Results This study included the 5693 adults recommended for statin therapy in the PALM (Patient and Provider Assessment of Lipid Management) registry. Patient surveys evaluated statin experience, reasons for declining or discontinuing statins, and beliefs about statins and cardiovascular disease risk. Overall, 1511 of 5693 adults (26.5%) were not on treatment. Of those not on a statin, 894 (59.2%) reported never being offered a statin, 153 (10.1%) declined a statin, and 464 (30.7%) had discontinued therapy. Women (relative risk: 1.22), black adults (relative risk: 1.48), and those without insurance (relative risk: 1.38) were most likely to report never being offered a statin. Fear of side effects and perceived side effects were the most common reasons cited for declining or discontinuing a statin. Compared with statin users, those who declined or discontinued statins were less likely to believe statins are safe (70.4% of current users vs. 36.9% of those who declined and 37.4% of those who discontinued) or effective (86.3%, 67.4%, and 69.1%, respectively). Willingness to take a statin was high; 67.7% of those never offered and 59.7% of patients who discontinued a statin would consider initiating or retrying a statin. Conclusions More than half of patients eligible for statin therapy but not on treatment reported never being offered one by their doctor. Concern about side effects was the leading reason for statin refusal or discontinuation. Many patients were willing to reconsider statin therapy if offered.
Teaching NeuroImages: Neuromyopathy in a patient with hereditary transthyretin Thr60Ala amyloidosis
Pinto, Marcus Vinícius , Tracy, Jennifer A., Grogan, Martha , Mauermann, Michelle L. , Pinto, Marcus V , Mauermann, Michelle L

Mayo Clinic

Neurology | March 19, 2019 | Volume: 92 | Issue: 12 | Pages: No page available

10.1212/wnl.0000000000007143 | PMID 30886082 Get It

Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer
Fritz, Andrew J. , Gerrard, Diana L., Hong, David I. , Rose, Joshua T., Ghule, Prachi N. , Bolf, Eric L. , Gordon, Jonathan , Tracy, Kirsten M. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Heath, Jessica L. , Frietze, Seth , Zaidi, Sayyed K. , Carr, Frances E. , Lian, Jane B. , Stein, Janet L. , Fritz, A J , Stein, Gary S , van Wijnen, Andre J , Tracy, Kirsten M , Gillis, Noelle E. , Rodriguez, Princess D. , Hong, D., Gordon, J.A., Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Genes, Chromosomes and Cancer | March 15, 2019 | Volume: 58 | Issue: 7 | Pages: 484-499

10.1002/gcc.22731 | PMID 30873710 Get It

Cells establish and sustain structural and functional integrity of the genome to support cellular identity and prevent malignant transformation. In this review, we present a strategic overview of epigenetic regulatory mechanisms including histone modifications and higher order chromatin organization (HCO) that are perturbed in breast cancer onset and progression. Implications for dysfunctions that occur in hormone regulation, cell cycle control, and mitotic bookmarking in breast cancer are considered, with an emphasis on epithelial‐to‐mesenchymal transition and cancer stem cell activities. The architectural organization of regulatory machinery is addressed within the contexts of translating cancer‐compromised genomic organization to advances in breast cancer risk assessment, diagnosis, prognosis, and identification of novel therapeutic targets with high specificity and minimal off target effects.
Onion‐bulb patterns predict acquired or inherited demyelinating polyneuropathy
Tracy, Jennifer A., Dyck, P. James B. , Engelstad, JaNean K., Meyer, Jane E., Klein, Christopher J. , Engelstad, JaNean , Meyer, Jane E.

Mayo Clinic

Muscle & Nerve | February 27, 2019 | Volume: 59 | Issue: 6 | Pages: 665-670

10.1002/mus.26452 | PMID 30810227 Get It

ABSTRACTIntroductionOnion‐bulbs (OB) are concentrically layered Schwann‐cell processes, surrounding nerve fibers, occurring in both inherited and acquired demyelinating polyneuropathies. We investigated whether OB patterns (generalized, mixed, or focal) correlate with acquired or inherited neuropathies.MethodsOne hundred thirty‐one OB‐rich nerve biopsies were graded for OB pattern and inflammation without knowledge of clinical history. We classified inherited (n = 49) or acquired (n = 82) neuropathies based solely on clinical history.ResultsFifty‐one biopsies had generalized (34 inherited vs. 17 acquired, P < 0.001), 54 mixed (48 acquired vs. 6 inherited, P < 0.001), and 26 focal/multifocal (inherited [n = 9], acquired [n = 17]) OB. Inflammation occurred more frequently in acquired (n = 54) than inherited (n = 14) neuropathy (P = 0.004).DiscussionGeneralized OB correlates with inherited neuropathy; mixed OB with acquired. Inflammation occurs more in acquired neuropathy cases. OB patterns are best explained by ubiquitous Schwann‐cell involvement in inherited and multifocal Schwann‐cell involvement in acquired neuropathies and predict the electrophysiology of uniform demyelination in inherited and unequal demyelination in acquired neuropathies. Muscle Nerve 59:665–670, 2019